Nanoform targets cost leadership for CESS platform as it scales commercial GMP output

Nanoform (NANOFH.HE) aims to make its CESS technology a cost leader against spray-dried amorphous solid dispersions by expanding clinical and commercial GMP CESS capacity in Helsinki for multi-ton annual production. The company plans to lower costs through higher yields, reduced excipient use, simplified processing, and lower capital requirements, while targeting higher drug loading to reduce pill burden and match or improve bioavailability.